QUESTIONS RAISED ABOUT A GERMAN LABORATORY LINKED TO HIGH-COST CELL-BASED TREATMENTS

February 5, 2026

Share this article

An examination of recorded conversations, published claims, and regulatory concerns

An independent investigation has raised serious questions about the role of a German laboratory, Ad Lentus, in the processing of blood-based therapies marketed to patients by Wellbeing International Foundation Ltd (WIF).


The concerns arise from a combination of published claims on Ad Lentus’s own website, recorded conversations involving its representatives, and expert opinion regarding laboratory capability and regulatory compliance.



Public claims of cancer treatment


On its publicly accessible website, Ad Lentus describes work involving autologous dendritic cell vaccines, which it characterises as a form of immunotherapy for the treatment of cancer. The website states that this approach falls within the category of Advanced Therapy Medicinal Products (ATMPs) and involves activating a patient’s immune system using cells derived from their own blood.


Such claims are significant. Under UK and EU law, the advertising and provision of cancer treatments are subject to strict regulation, and therapies described as ATMPs are normally required to undergo extensive authorisation, clinical trials, and regulatory approval.


Experts consulted for this investigation noted that publicly claiming to provide cancer treatments based on cell-derived products would typically require demonstrable compliance with Good Manufacturing Practice (GMP) standards and oversight by medicines regulators.


Recorded conversation with laboratory representative


As part of the investigation, an undercover operative (UC) participated in a recorded Zoom call involving Jörn Steiger, who is presented on the Ad Lentus website as a member of its team, and Andrew Chancellor, who has previously been recorded promoting high-cost treatments on behalf of WIF.


The recordings and transcripts have been preserved as exhibits and, according to the investigators, copies have been provided to both the US Food and Drug Administration (FDA) and the UK Serious Fraud Office (SFO).


During the call, Chancellor describes a long-standing working relationship between himself, Steven Ray, and Steiger, stating that they have collaborated since around 2010–2011 on various cell-based protocols.

Steiger confirms that Ad Lentus carries out laboratory work “according to GMP standards” and says the laboratory performs protocols designed by WIF.


Description of laboratory processes


In the recorded exchange, Steiger explains that blood-derived cells are isolated and then subjected to a form of stress intended to stimulate the release of cytokines and microvesicles. He states that no drugs or chemical additives are introduced and that the final infused product consists solely of material derived from the patient.

Steiger characterises this process as accelerating what cells would “normally do under natural conditions,” producing what he describes as “help factors” released in response to stress.


However, independent experts later told the investigation that the description provided raises questions about whether the laboratory processes described are sufficient to produce a consistent, clinically meaningful therapeutic product — particularly one claimed to have effects on cancer, inflammation, or tissue repair.


Questions about laboratory capability


Investigators say they have received information from a person familiar with the Ad Lentus laboratory setup suggesting that the facility does not possess the specialist equipment required to carry out the advanced cell processing described. That individual has not been identified due to safety and professional concerns.


While this claim cannot be independently verified at this stage, experts consulted for the investigation noted that producing ATMP-class therapies typically requires highly specialised infrastructure, validated processes, and regulatory oversight.


One scientist described the gap between how such therapies are discussed in marketing materials and what is realistically achievable in many private laboratories as “a recurring issue in this sector.”


Wider concerns about blood handling and oversight


The recorded conversations also raise questions about how patient blood is collected, transported, processed, and returned.


In earlier undercover recordings involving WIF representatives, patients were told that blood could be collected at home, shipped internationally, processed, and later re-infused — sometimes without involvement from the patient’s own doctor.


Investigators say they have identified the company used to transport blood to Germany and are examining whether appropriate licences and authorisations were in place. These issues will be examined in further reporting.


Context: a growing and controversial industry


Cell-based and “regenerative” therapies have become a rapidly expanding global industry, often operating in regulatory grey areas. Scientists and regulators have repeatedly warned that complex biological terminology can be used to give an impression of legitimacy without corresponding clinical evidence.


Experts consulted for this investigation emphasised that claims relating to cancer treatment, immune system “education,” or disease modification require especially robust evidence.


Public interest


This article is based on recorded conversations, published website material, and expert analysis. It does not make findings of criminal liability.


The purpose of publication is to highlight practices and claims that independent experts say warrant closer scrutiny by regulators, particularly where laboratory-processed blood products are promoted for serious medical conditions.


Individuals and organisations named have been given, or will be given, an opportunity to respond as further reporting continues.



This article is published in the public interest.

Recent Posts

May 15, 2026
For months, investigators have examined the digital footprint, corporate structure, public marketing, and leadership profiles connected to Wellbeing International Foundation Ltd.
May 15, 2026
As investigators continued examining the structure behind Wellbeing International Foundation Ltd,
May 10, 2026
WELLBEING INTERNATIONAL FOUNDATION TESTIMONIALS
May 10, 2026
WELLBEING INTERNATIONAL FOUNDATION LTD: “ETHICAL HEALING”
May 3, 2026
The commercial stem cell industry has grown rapidly over the past decade, with clinics around the world advertising regenerative medicine programs for conditions ranging from chronic pain to neurological disorders. Among the most controversial areas is autism. Families searching online are now routinely exposed to clinics promoting stem cell therapies as potential solutions for behavioural, developmental, or communication difficulties associated with autism spectrum disorder (ASD). But according to major medical authorities, parents should be extremely careful before committing to expensive experimental treatments. No Major Regulator Has Approved Stem Cell Therapy For Autism At present: The U.S. Food and Drug Administration has not approved stem cell therapy as a treatment for autism. The National Health Service does not recognise stem cell therapy as a standard autism treatment. European regulators continue treating most autism-related stem cell therapies as experimental. Researchers continue studying the field. But experimental science and established medical treatment are not the same thing. The Problem With Commercial Marketing Critics argue that some clinics blur the line between scientific possibility and proven outcome. Common marketing techniques include: Emotional recovery stories Before-and-after videos Technical medical language Claims of “advanced” therapy References to inflammation or neurological repair However, many scientists say evidence supporting these claims remains limited or inconclusive. Understanding Autism Complexity Autism is not a single illness. It is a broad developmental spectrum involving: Communication differences Behavioural traits Sensory variation Neurological diversity Because autism naturally develops differently in every child, measuring treatment success becomes highly complicated. Experts warn that developmental progress may sometimes occur naturally over time regardless of experimental intervention. What Treatments Have Better Scientific Support? While no treatment cures autism, specialists generally recommend evidence-based support approaches such as: Speech and language therapy Occupational therapy Behavioural intervention Educational support Social development programs Family support services Major organisations providing evidence-based information include: National Autistic Society https://www.autism.org.uk/ Centers for Disease Control and Prevention https://www.cdc.gov/autism/ World Health Organization https://www.who.int/ Autism Speaks https://www.autismspeaks.org/ Questions Families Should Ask Before Paying Experts recommend parents ask: Is this treatment regulator-approved? What peer-reviewed evidence exists? What are the known risks? What percentage of patients show no benefit? Are claims independently verified?  Evidence Before Emotion Families searching for hope deserve compassion, transparency, and honesty. Stem cell science remains an active research field. But until stronger clinical evidence exists, many experts believe autism-related stem cell treatments should be approached with serious caution — particularly when large sums of money and vulnerable families are involved.
May 3, 2026
As commercial stem cell clinics continue expanding across Europe and beyond, increasing numbers of families affected by autism are being introduced to expensive regenerative medicine programs marketed as cutting-edge alternatives to conventional therapy. One organisation repeatedly mentioned during conversations with former clients and concerned families is Wellbeing International Foundation LTD. This article does not accuse the clinic of criminal behaviour or fraud. However, as concerns surrounding commercial autism-related stem cell treatments continue growing internationally, experts say families should approach all such clinics with careful scrutiny. Why Autism Has Become A High-Interest Market Autism spectrum disorder affects millions of families worldwide. Because there is no single cure — and because developmental progress can vary enormously from child to child — families are often vulnerable to treatments marketed as innovative or revolutionary. Investigators reviewing the regenerative medicine sector have identified repeated themes in clinic advertising: Hope-based messaging Emotional testimonials Scientific jargon “Breakthrough” language Claims of advanced neurological repair Large financial commitments For many parents, distinguishing between genuine science and commercial optimism can become extremely difficult. THE MAIN WARNING SIGNS 🚩 Clinics Suggesting One Treatment Can Help Many Conditions Experts urge caution when the same therapy is promoted for: Autism Neurological disease Chronic pain Anti-ageing Immune conditions Degenerative illness Complex medical conditions require highly specific evidence. 🚩 Testimonials Used As Primary Evidence Powerful personal stories can influence emotions deeply. But regulators repeatedly warn that testimonials alone do not prove clinical effectiveness. 🚩 Scientific Terminology Without Clear Proof Families should ask clinics to clearly explain: How treatments work What evidence exists What outcomes are independently verified Complicated language is not the same as scientific certainty. 🚩 Significant Financial Commitments Many families report spending very large sums on: Consultations Treatment programs Flights Accommodation Repeat procedures without guaranteed outcomes. 🚩 Overseas Structures And Limited Oversight International treatment arrangements can complicate: Legal accountability Consumer rights Medical regulation Long-term follow-up The Ethics Of Hope Medical ethics experts have increasingly raised concerns about the emotional vulnerability of families searching for autism support. Parents naturally want to help their children. That emotional reality can make high-promise treatments especially persuasive. Critics argue that hope should never be marketed in a way that risks creating unrealistic expectations.  Questions Families Should Always Ask Before committing to any stem cell-based autism treatment, families should request: Published evidence Independent clinical data Long-term outcomes Full risk disclosures Regulatory status information Transparency matters. Especially when vulnerable families are involved.
May 3, 2026
For many parents raising children with autism, life becomes a constant search for answers. Therapies. Specialists. Diets. Support groups. New research. Alternative medicine. And increasingly, stem cell clinics. Over recent months, Investigations Desk has spoken with families who say they pursued expensive regenerative medicine treatments for autistic children after being exposed to persuasive marketing campaigns promising potential improvements in communication, behaviour, focus, and cognitive function. One parent — who we will identify only as Mr X to protect the child’s privacy — described a journey that began with optimism but eventually turned into doubt. According to Mr X, the family underwent multiple treatment procedures after being encouraged to believe stem cell-based therapies could potentially assist with autism-related symptoms. Initially, every small behavioural change felt significant. But over time, the family says they began questioning whether the treatments had actually produced any measurable improvement at all. “You want to believe something is happening,” Mr X explained. “As a parent, you analyse every little change because you desperately want your child to improve.” The family says the emotional pressure surrounding the process made objective judgment increasingly difficult. The Rise Of Autism As A Commercial Treatment Market Autism spectrum disorder has become one of the fastest-growing target areas within the global regenerative medicine industry. Across websites and social media platforms, clinics frequently advertise: Stem cell therapy Exosome therapy Neuro-regenerative medicine Immune modulation programs Cellular repair treatments Many use emotional testimonials alongside highly technical scientific language which can be difficult for ordinary families to independently verify. Investigators examining this sector have repeatedly identified recurring marketing patterns: Dramatic recovery stories Scientific terminology with limited explanation Expensive treatment packages Overseas treatment arrangements “Breakthrough” medical language Claims that conventional medicine is “behind” What Science Currently Says Despite aggressive online marketing, there is currently no universally accepted regulator-approved stem cell cure for autism. Research into stem cells and neurological conditions does exist. However, leading experts continue warning that experimental research should not be confused with established medical treatment. Autism itself is an extremely complex developmental condition involving a broad spectrum of behavioural and neurological differences. That complexity makes it particularly difficult to scientifically measure treatment claims being promoted commercially. Hope And Vulnerability Parents affected by autism are not foolish for exploring possibilities. They are hopeful. And hope can become extremely powerful when families feel conventional support systems are slow, limited, or overwhelmed. Critics of the commercial stem cell industry argue that some clinics may unintentionally blur the line between experimental science and proven medical outcomes. That concern is now drawing increasing international attention from regulators, scientists, and consumer protection groups.  The Bigger Question Mr X says the family eventually decided to speak privately with investigators after recognising similarities between their experience and concerns now being raised globally about commercial regenerative medicine businesses. “We’re not against research,” he said. “But families need to know the difference between evidence and hope.” That distinction may now sit at the heart of one of the most controversial debates in modern alternative medicine.
April 24, 2026
There is a pattern. Once you’ve seen it, you can’t unsee it.
Show More